APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Immunodeficiency Virus Type-1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Immunodeficiency Virus Type-1 Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchHuman Immunodeficiency Virus Type-1 Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunodeficiency Virus Type-1 Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Human Immunodeficiency Virus Type-1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunodeficiency Virus Type-1 Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunodeficiency Virus Type-1 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Human Immunodeficiency Virus Type-1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Immunodeficiency Virus Type-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunodeficiency Virus Type-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunodeficiency Virus Type-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Immunodeficiency Virus Type-1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Immunodeficiency Virus Type-1 market include AstraZeneca, Bayer, Bristol Myers Squibb, Merck & Co. Inc., Novartis, Pfizer, Viatris, GSK and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Immunodeficiency Virus Type-1 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunodeficiency Virus Type-1 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunodeficiency Virus Type-1 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Immunodeficiency Virus Type-1 market.

Human Immunodeficiency Virus Type-1 Segment by Company

AstraZeneca

Bayer

Bristol Myers Squibb

Merck & Co. Inc.

Novartis

Pfizer

Viatris

GSK

Roche

Sanofi

Human Immunodeficiency Virus Type-1 Segment by Type

Integrase Inhibitor

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Protease Inhibitors (PIs)

Others

Human Immunodeficiency Virus Type-1 Segment by Application

Retail Pharmacies

Hospital Pharmacies

Human Immunodeficiency Virus Type-1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Immunodeficiency Virus Type-1 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Immunodeficiency Virus Type-1 key companies, revenue, market share, and recent developments.

3. To split the Human Immunodeficiency Virus Type-1 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Immunodeficiency Virus Type-1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Immunodeficiency Virus Type-1 significant trends, drivers, influence factors in global and regions.

6. To analyze Human Immunodeficiency Virus Type-1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunodeficiency Virus Type-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunodeficiency Virus Type-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunodeficiency Virus Type-1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Immunodeficiency Virus Type-1 industry.

Chapter 3: Detailed analysis of Human Immunodeficiency Virus Type-1 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Immunodeficiency Virus Type-1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Immunodeficiency Virus Type-1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Immunodeficiency Virus Type-1 Industry Trends Table 2. Human Immunodeficiency Virus Type-1 Industry Drivers Table 3. Human Immunodeficiency Virus Type-1 Industry Opportunities and Challenges Table 4. Human Immunodeficiency Virus Type-1 Industry Restraints Table 5. Global Human Immunodeficiency Virus Type-1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Immunodeficiency Virus Type-1 Revenue Share by Company (2021-2026) Table 7. Global Human Immunodeficiency Virus Type-1 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Immunodeficiency Virus Type-1 Key Company Manufacturing Base & Headquarters Table 9. Global Human Immunodeficiency Virus Type-1 Company, Product Type & Application Table 10. Global Human Immunodeficiency Virus Type-1 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Immunodeficiency Virus Type-1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Integrase Inhibitor Table 15. Significant Companies of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Table 16. Significant Companies of Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Table 17. Significant Companies of Protease Inhibitors (PIs) Table 18. Significant Companies of Others Table 19. Global Human Immunodeficiency Virus Type-1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Human Immunodeficiency Virus Type-1 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Human Immunodeficiency Virus Type-1 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Type (2021-2026) Table 23. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Retail Pharmacies Table 25. Significant Companies of Hospital Pharmacies Table 26. Global Human Immunodeficiency Virus Type-1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Human Immunodeficiency Virus Type-1 Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Human Immunodeficiency Virus Type-1 Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Application (2021-2026) Table 30. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Application (2027-2032) Table 31. Global Human Immunodeficiency Virus Type-1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Human Immunodeficiency Virus Type-1 Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Region (2021-2026) Table 34. Global Human Immunodeficiency Virus Type-1 Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Region (2027-2032) Table 36. Global Human Immunodeficiency Virus Type-1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human Immunodeficiency Virus Type-1 Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Human Immunodeficiency Virus Type-1 Sales Value Market Share by Country (2021-2026) Table 39. Global Human Immunodeficiency Virus Type-1 Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Human Immunodeficiency Virus Type-1 Sales Value Market Share by Country (2027-2032) Table 41. AstraZeneca Company Information Table 42. AstraZeneca Business Overview Table 43. AstraZeneca Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. AstraZeneca Human Immunodeficiency Virus Type-1 Product Portfolio Table 45. AstraZeneca Recent Development Table 46. Bayer Company Information Table 47. Bayer Business Overview Table 48. Bayer Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bayer Human Immunodeficiency Virus Type-1 Product Portfolio Table 50. Bayer Recent Development Table 51. Bristol Myers Squibb Company Information Table 52. Bristol Myers Squibb Business Overview Table 53. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Portfolio Table 55. Bristol Myers Squibb Recent Development Table 56. Merck & Co. Inc. Company Information Table 57. Merck & Co. Inc. Business Overview Table 58. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Portfolio Table 60. Merck & Co. Inc. Recent Development Table 61. Novartis Company Information Table 62. Novartis Business Overview Table 63. Novartis Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Novartis Human Immunodeficiency Virus Type-1 Product Portfolio Table 65. Novartis Recent Development Table 66. Pfizer Company Information Table 67. Pfizer Business Overview Table 68. Pfizer Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Pfizer Human Immunodeficiency Virus Type-1 Product Portfolio Table 70. Pfizer Recent Development Table 71. Viatris Company Information Table 72. Viatris Business Overview Table 73. Viatris Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Viatris Human Immunodeficiency Virus Type-1 Product Portfolio Table 75. Viatris Recent Development Table 76. GSK Company Information Table 77. GSK Business Overview Table 78. GSK Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. GSK Human Immunodeficiency Virus Type-1 Product Portfolio Table 80. GSK Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Roche Human Immunodeficiency Virus Type-1 Product Portfolio Table 85. Roche Recent Development Table 86. Sanofi Company Information Table 87. Sanofi Business Overview Table 88. Sanofi Human Immunodeficiency Virus Type-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sanofi Human Immunodeficiency Virus Type-1 Product Portfolio Table 90. Sanofi Recent Development Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Human Immunodeficiency Virus Type-1 Product Image Figure 2. Global Human Immunodeficiency Virus Type-1 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunodeficiency Virus Type-1 Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Immunodeficiency Virus Type-1 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Integrase Inhibitor Image Figure 8. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Image Figure 9. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Image Figure 10. Protease Inhibitors (PIs) Image Figure 11. Others Image Figure 12. Global Human Immunodeficiency Virus Type-1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Human Immunodeficiency Virus Type-1 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Type (2021-2032) Figure 15. Retail Pharmacies Image Figure 16. Hospital Pharmacies Image Figure 17. Global Human Immunodeficiency Virus Type-1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human Immunodeficiency Virus Type-1 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Application (2021-2032) Figure 20. Global Human Immunodeficiency Virus Type-1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Human Immunodeficiency Virus Type-1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Human Immunodeficiency Virus Type-1 Sales Value (2021-2032) & (US$ Million) Figure 23. North America Human Immunodeficiency Virus Type-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Human Immunodeficiency Virus Type-1 Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Human Immunodeficiency Virus Type-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Human Immunodeficiency Virus Type-1 Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Human Immunodeficiency Virus Type-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Human Immunodeficiency Virus Type-1 Sales Value (2021-2032) & (US$ Million) Figure 29. South America Human Immunodeficiency Virus Type-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Human Immunodeficiency Virus Type-1 Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Human Immunodeficiency Virus Type-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Integrase Inhibitor
  • Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (PIs)
  • Others
Applications
  • Retail Pharmacies
  • Hospital Pharmacies
Companies covered
  • AstraZeneca
  • Bayer
  • Bristol Myers Squibb
  • Merck & Co. Inc.
  • Novartis
  • Pfizer
  • Viatris
  • GSK
  • Roche
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Immunodeficiency Virus Type-1 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Immunodeficiency Virus Type-1 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Immunodeficiency Virus Type-1 Market Dynamics
  1. 2.1 Human Immunodeficiency Virus Type-1 Industry Trends
  2. 2.2 Human Immunodeficiency Virus Type-1 Industry Drivers
  3. 2.3 Human Immunodeficiency Virus Type-1 Industry Opportunities and Challenges
  4. 2.4 Human Immunodeficiency Virus Type-1 Industry Restraints
3 Human Immunodeficiency Virus Type-1 Market by Company
  1. 3.1 Global Human Immunodeficiency Virus Type-1 Company Revenue Ranking in 2025
  2. 3.2 Global Human Immunodeficiency Virus Type-1 Revenue by Company (2021-2026)
  3. 3.3 Global Human Immunodeficiency Virus Type-1 Company Ranking (2024-2026)
  4. 3.4 Global Human Immunodeficiency Virus Type-1 Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Immunodeficiency Virus Type-1 Company Product Type and Application
  6. 3.6 Global Human Immunodeficiency Virus Type-1 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Immunodeficiency Virus Type-1 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Immunodeficiency Virus Type-1 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Immunodeficiency Virus Type-1 Market by Type
  1. 4.1 Human Immunodeficiency Virus Type-1 Type Introduction
  2. 4.1.1 Integrase Inhibitor
  3. 4.1.2 Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
  4. 4.1.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  5. 4.1.4 Protease Inhibitors (PIs)
  6. 4.1.5 Others
  7. 4.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Type
  8. 4.2.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Type (2021-2032)
  10. 4.2.3 Global Human Immunodeficiency Virus Type-1 Sales Value Share by Type (2021-2032)
5 Human Immunodeficiency Virus Type-1 Market by Application
  1. 5.1 Human Immunodeficiency Virus Type-1 Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Application
  5. 5.2.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Application (2021-2032)
  7. 5.2.3 Global Human Immunodeficiency Virus Type-1 Sales Value Share by Application (2021-2032)
6 Human Immunodeficiency Virus Type-1 Regional Value Analysis
  1. 6.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Immunodeficiency Virus Type-1 Sales Value (2021-2032)
  7. 6.3.2 North America Human Immunodeficiency Virus Type-1 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Immunodeficiency Virus Type-1 Sales Value (2021-2032)
  10. 6.4.2 Europe Human Immunodeficiency Virus Type-1 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Immunodeficiency Virus Type-1 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Immunodeficiency Virus Type-1 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Immunodeficiency Virus Type-1 Sales Value (2021-2032)
  16. 6.6.2 South America Human Immunodeficiency Virus Type-1 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Immunodeficiency Virus Type-1 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Immunodeficiency Virus Type-1 Sales Value Share by Country, 2025 VS 2032
7 Human Immunodeficiency Virus Type-1 Country-level Value Analysis
  1. 7.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Immunodeficiency Virus Type-1 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Immunodeficiency Virus Type-1 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Immunodeficiency Virus Type-1 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Immunodeficiency Virus Type-1 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Immunodeficiency Virus Type-1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Human Immunodeficiency Virus Type-1 Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Human Immunodeficiency Virus Type-1 Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Bristol Myers Squibb
  14. 8.3.1 Bristol Myers Squibb Company Information
  15. 8.3.2 Bristol Myers Squibb Business Overview
  16. 8.3.3 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb Human Immunodeficiency Virus Type-1 Product Portfolio
  18. 8.3.5 Bristol Myers Squibb Recent Developments
  19. 8.4 Merck & Co. Inc.
  20. 8.4.1 Merck & Co. Inc. Company Information
  21. 8.4.2 Merck & Co. Inc. Business Overview
  22. 8.4.3 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co. Inc. Human Immunodeficiency Virus Type-1 Product Portfolio
  24. 8.4.5 Merck & Co. Inc. Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Human Immunodeficiency Virus Type-1 Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Human Immunodeficiency Virus Type-1 Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Viatris
  38. 8.7.1 Viatris Company Information
  39. 8.7.2 Viatris Business Overview
  40. 8.7.3 Viatris Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Viatris Human Immunodeficiency Virus Type-1 Product Portfolio
  42. 8.7.5 Viatris Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Human Immunodeficiency Virus Type-1 Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Human Immunodeficiency Virus Type-1 Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Human Immunodeficiency Virus Type-1 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Human Immunodeficiency Virus Type-1 Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst